Outlook Therapeutics, Inc.
For the period ended Sep 30, 2025. Filed Dec 19, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Dec 19, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
ITEM 16. Form 10-K Summary
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Date: December 19, 2025 | By: | /s/ Robert C. Jahr |
|---|---|---|
| Name: | Robert C. Jahr | |
| Title: | Chief Executive Officer |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| /s/ Faisal G. Sukhtian | | Chairman | | December 19, 2025 |
|---|---|---|---|---|
| Faisal G. Sukhtian | | | ||
| | | |||
| /s/ Robert C. Jahr | | Chief Executive Officer | | December 19, 2025 |
| Robert C. Jahr | | (Principal Executive Officer) | | |
| | | |||
| /s/ Lawrence A. Kenyon | | Chief Financial Officer | | December 19, 2025 |
| Lawrence A. Kenyon | | Treasurer, Secretary and Director (Principal Financial and Accounting Officer) | | |
| | | |||
| /s/ Kurt J. Hilzinger | | Director | | December 19, 2025 |
| Kurt J. Hilzinger | | | ||
| | | |||
| /s/ Yezan Haddadin | | Director | | December 19, 2025 |
| Yezan Haddadin | | | | |
| | | | | |
| /s/ Julia A. Haller | | Director | | December 19, 2025 |
| Julia A. Haller | | | | |
| | | | | |
| /s/ Ralph H. Thurman | | Director | | December 19, 2025 |
| Ralph H. Thurman | | | ||
| | | | | |
| /s/ Julian Gangolli | | Director | | December 19, 2025 |
| Julian Gangolli | | | | |
| | | | | |
| /s/ Gerd Auffarth | | Director | | December 19, 2025 |
| Gerd Auffarth | | | | |
| | | | | |
| /s/ Andong Huang | | Director | | December 19, 2025 |
| Andong Huang | | | | |
| | | | | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.